CN Bio, a leading provider of organ-on-a-chip (OOC) systems and solutions, has announced a long-term strategic partnership with Pharmaron, a top-tier research and development service provider in the life sciences industry. The collaboration aims to develop OOC technology on a global platform and integrate it into Pharmaron’s existing R&D processes. The partnership’s initial phase will focus on validating CN Bio’s PhysioMimix® technology in several key areas, including disease modeling, toxicity testing, and studies on drug absorption, distribution, metabolism, and excretion (ADME). Upon successful validation, the two companies will work together to adopt the platform in priority research domains and explore new applications to address unmet needs in drug discovery and development. Pharmaron operates as a global drug R&D service platform, offering comprehensive services from drug discovery through preclinical and clinical development. As part of this collaboration, CN Bio will install its PhysioMimix instruments in Pharmaron’s facilities worldwide, enabling the joint development of customized, cutting-edge OOC solutions to tackle evolving research challenges. CN Bio's CEO, Dr. Paul Brooks, stated, “Pharmaron is a global and trusted leader in the life sciences industry. Their expertise aligns perfectly with our goals of expanding our OOC solution portfolio in both new and established application areas. By closely collaborating and leveraging the complementary strengths of both companies, we can share resources and bring innovative solutions from concept to market deployment more efficiently than ever before.” Dr. Tomasz Kostrzewski, CN Bio’s Chief Scientific Officer, added, “The recent announcement by the U.S. Food and Drug Administration (FDA) to phase out animal testing requirements for monoclonal antibodies and other drugs in favor of human-relevant models makes this partnership particularly significant. Our platform is well-suited to fill current market gaps, such as detecting immune-mediated organ damage. Together, we can accelerate this crucial advancement, aligning with global trends toward more ethical and cost-effective drug development that ultimately improves human health.” Pharmaron’s Chief Scientific Officer, Dr. Hua Yang, commented, “We are committed to continuous innovation to enhance our service quality and speed up drug discovery and development. Organ-on-a-chip technology holds great potential to deepen our understanding of drug developability during the preclinical stage, thereby advancing translational science. We are excited to collaborate with CN Bio to discover how this technology can add meaningful value to our partners’ development projects.” Disclaimer: The original version of this announcement is the official and legally binding document. This translated version is provided for convenience only. Please refer to the original document for the definitive legal content.